Literature DB >> 21670974

Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules.

Peter Loewen1, Karen Dahri.   

Abstract

This study aimed to determine whether progress in developing bleeding risk estimation tools for patients on oral anticoagulant therapy has been made since 2006 when we last systematically reviewed this topic, and to refresh previously published quantitative evaluations of the clinical prediction rules (CPRs) available for estimating bleeding risk in patients on oral anticoagulant therapy. A systematic review of English language literature published since December 2006 was conducted when our previous systematic review ended. Studies were analyzed for predictive performance using likelihood ratios. Six studies detailed CPRs used to assess risk of bleeding prior to commencing warfarin therapy, four of which were included in the analysis. Three studies evaluated new CPRs ("RIETE" and "HAS-BLED"). One of the studies was a further validation of the modified outpatient bleeding risk index (mOBRI) in patients with atrial fibrillation. Individual trial and pooled analyses using likelihood ratios for mOBRI and HAS-BLED showed they have weak predictive accuracy. A RIETE score of 0 point was moderately predictive of the absence of major bleeding. None of the CPRs exhibited sufficient predictive accuracy or had sufficient validation to be recommended for routine use in practice. None of the available CPRs exhibit sufficient predictive accuracy or have trials evaluating the impact of their use on patient outcomes. Hence, no existing oral anticoagulation major bleeding CPR can be recommended for routine use in practice at present.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21670974     DOI: 10.1007/s00277-011-1267-3

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  15 in total

1.  Aortic biological valve prosthesis in patients younger than 65 years of age: transition to a flexible age limit?

Authors:  Lars Niclauss; Ludwig Karl von Segesser; Enrico Ferrari
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-01-03

2.  To anticoagulate or not to anticoagulate? That is the question : A Medline-based quantitative approach to share evidence on common clinical problems.

Authors:  Simone Birocchi; Giulia Cernuschi; Gian Marco Podda; Giorgio Costantino
Journal:  Intern Emerg Med       Date:  2012-07-31       Impact factor: 3.397

Review 3.  Anticoagulation of Cardiovascular Conditions in the Cancer Patient: Review of Old and New Therapies.

Authors:  Isaac B Rhea; Alexander R Lyon; Michael G Fradley
Journal:  Curr Oncol Rep       Date:  2019-04-04       Impact factor: 5.075

4.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  Circulation       Date:  2014-03-28       Impact factor: 29.690

Review 5.  Anticoagulants in atrial fibrillation patients with chronic kidney disease.

Authors:  Robert G Hart; John W Eikelboom; Alistair J Ingram; Charles A Herzog
Journal:  Nat Rev Nephrol       Date:  2012-07-24       Impact factor: 28.314

6.  Body mass index predicts major bleeding risks in patients on warfarin.

Authors:  Adedotun A Ogunsua; Sunkaru Touray; Justin K Lui; Tiffany Ip; Jorge V Escobar; Joel Gore
Journal:  J Thromb Thrombolysis       Date:  2015-11       Impact factor: 2.300

7.  Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).

Authors:  Shaun G Goodman; Daniel M Wojdyla; Jonathan P Piccini; Harvey D White; John F Paolini; Christopher C Nessel; Scott D Berkowitz; Kenneth W Mahaffey; Manesh R Patel; Matthew W Sherwood; Richard C Becker; Jonathan L Halperin; Werner Hacke; Daniel E Singer; Graeme J Hankey; Gunter Breithardt; Keith A A Fox; Robert M Califf
Journal:  J Am Coll Cardiol       Date:  2013-12-04       Impact factor: 24.094

Review 8.  Phenotyping bleeding.

Authors:  Paula James; Barry S Coller
Journal:  Curr Opin Hematol       Date:  2012-09       Impact factor: 3.284

9.  Variation in bleeding risk estimates among online calculators: Cross-sectional study of apps used by and for patients with atrial fibrillation.

Authors:  Ryan Pelletier; Jeff Nagge; John-Michael Gamble
Journal:  Can Fam Physician       Date:  2022-04       Impact factor: 3.275

Review 10.  Drug Treatment of Venous Thromboembolism in the Elderly.

Authors:  Jir Ping Boey; Alexander Gallus
Journal:  Drugs Aging       Date:  2016-07       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.